Australia Make A Note Of This Date – Next Week TGA To Deliver Interim Decision On Declassifying MDMA & Psilocybin For Clinical Purposes.

The Therapeutic Goods Administration (TGA) is set to deliver an interim decision next week on whether to declassify the illegal substances MDMA and psilocybin for clinical purposes.

The Tasmanian Examiner reports

They are currently listed as prohibited substances, sitting alongside drugs such as heroin and cannabis, but psychedelic therapy proponent Mind Medicine Australia has applied for the drugs to become controlled substances, like morphine and ketamine.

This means they could more easily be used as treatments for mental illness in controlled medical environments, but The Royal Australian and New Zealand College of Psychiatrists (RANZCP) warns that the efficacy and safety of such therapies are as yet unknown.

While there is emerging evidence for the use of psychedelic therapies in the treatment of mental illnesses, further work needs to occur before it can be considered a safe and effective intervention in clinical practice.

RANZCP

RANZCP Tasmanian branch chair Ben Elijah said more research into MDMA and psilocybin is necessary to inform future potential use in psychiatric practice.

“While there is emerging evidence for the use of psychedelic therapies in the treatment of mental illnesses, further work needs to occur before it can be considered a safe and effective intervention in clinical practice,” Dr Elijah said.

“As psychiatrists, we must promote evidence-based best-practice advice on new and emerging treatments for mental health.

Latest posts